Recombinant human acid α-glucosidase enzyme therapy for infantile glycogen storage disease type II: Results of a phase I/II clinical trial-Reference-Cited by-同舟云学术

Recombinant human acid α-glucosidase enzyme therapy for infantile glycogen storage disease type II: Results of a phase I/II clinical trial

Published:2001-03 Issue:2 Volume:3 Page:132-138
ISSN:1098-3600
Container-title:Genetics in Medicine
language:en
Short-container-title:Genetics in Medicine

Author:

Amalfitano Andrea,Bengur A. Resai,Morse Richard P.,Majure Joseph M.,Case Laura E.,Veerling Deborah L.,Mackey Joanne,Kishnani Priya,Smith Wendy,McVie-Wylie Alison,Sullivan Jennifer A.,Hoganson George E.,Phillips John A.,Schaefer G. Bradley,Charrow Joel,Ware Russell E.,Bossen Edward H.,Chen Yuan-Tsong

Publisher

Elsevier BV

Subject

Genetics (clinical)

Link

http://www.nature.com/articles/gim200127.pdf

Reference20 articles.

1. Glycogen storage disease type II: acid α-glucosidase (acid maltase) deficiency;Hirschhorn;The metabolic and molecular basis of inherited disease,1995

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers;Frontiers in Oncology;2024-04-19

2. An updated management approach of Pompe disease patients with high-sustained anti-rhGAA IgG antibody titers: experience with bortezomib-based immunomodulation;Frontiers in Immunology;2024-03-08

3. Glycogen‐binding protein STBD1: Molecule and role in pathophysiology;Journal of Cellular Physiology;2023-07-12

4. Benefits of Prophylactic Short-Course Immune Tolerance Induction in Patients With Infantile Pompe Disease: Demonstration of Long-Term Safety and Efficacy in an Expanded Cohort;Frontiers in Immunology;2020-08-06

5. Distrofie muscolari;Terapia delle malattie neurologiche;2009